Active Ingredient History
Semaglutide (trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. Semaglutide is a once-daily glucagon-like peptide-1 analog that differs to others by the presence of an acyl group with a steric diacid at Lys26 and a large synthetic spacer and modified by the presence of a α-aminobutyric acid in position 8 which gives stability against the dipeptidylpeptidase-4. Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Aging (Phase 4)
Albuminuria (Phase 3)
Alcoholism (Phase 2)
Alzheimer Disease (Phase 3)
Asthma (Phase 2)
Atherosclerosis (Phase 4)
Atrial Fibrillation (Phase 4)
Behavior, Addictive (Phase 2)
Biomarkers (Phase 4)
Body Weight (Phase 3)
Body Weight Changes (Phase 4)
Body-Weight Trajectory (Phase 3)
Bone Diseases, Metabolic (Phase 2)
Brain Diseases (Phase 2)
Cardiomyopathies (Phase 2)
Cardiovascular Diseases (Phase 4)
Central Nervous System (Phase 4)
Cigarette Smoking (Phase 2)
Clozapine (Phase 4)
Cognitive Dysfunction (Phase 2)
Coronary Artery Disease (Phase 4)
COVID-19 (Phase 2)
Cystic Fibrosis (Phase 2/Phase 3)
Depressive Disorder, Major (Phase 2)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetic Nephropathies (Phase 3)
Digestive System Diseases (Phase 2)
Drugs, Investigational (Phase 4)
Dysgeusia (Phase 4)
Endometrial Hyperplasia (Phase 2)
Endometrial Neoplasms (Phase 2)
Endothelial Cells (Phase 4)
Endothelial Progenitor Cells (Phase 4)
Fibrosis (Phase 4)
Gastric Emptying (Phase 4)
Genetic Predisposition to Disease (Phase 4)
Glucagon-Like Peptide 1 (Phase 4)
Glycemic Control (Phase 3)
Healthy Volunteers (Phase 4)
Heart Failure, Diastolic (Phase 2)
HIV Infections (Phase 2)
Hypercholesterolemia (Phase 1)
Hyperglycemia (Phase 4)
Hyperplasia (Phase 2)
Hypertension, Pulmonary (Phase 1/Phase 2)
Incretins (Phase 4)
Inflammation (Phase 4)
Infusions, Intravenous (Phase 2)
Insulin Resistance (Phase 4)
Intestinal Neoplasms (Phase 4)
Intracranial Pressure (Phase 4)
Ischemic Stroke (Phase 2)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 2)
Klinefelter Syndrome (Phase 3)
Liver (Phase 4)
Liver Cirrhosis (Phase 4)
Liver Diseases (Phase 4)
Liver Transplantation (Phase 4)
Lung Diseases, Interstitial (Phase 1/Phase 2)
Metabolic Diseases (Phase 4)
Metabolic Syndrome (Phase 3)
Metabolism (Phase 3)
Multiple Myeloma (Phase 1)
Myocardium (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity (Phase 4)
Obesity, Morbid (Phase 3)
Olanzapine (Phase 4)
Overweight (Phase 4)
Papilledema (Phase 4)
Parkinson Disease (Phase 2)
Pediatric Obesity (Phase 4)
Peripheral Arterial Disease (Phase 3)
Polycystic Ovary Syndrome (Phase 4)
Postpartum Period (Phase 4)
Prediabetic State (Phase 4)
Pseudotumor Cerebri (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 1/Phase 2)
Renal Insufficiency, Chronic (Phase 3)
Sarcoidosis, Pulmonary (Phase 1/Phase 2)
Schizophrenia (Phase 4)
Scleroderma, Systemic (Phase 1)
Sodium-Glucose Transporter 2 Inhibitors (Phase 4)
Stroke (Phase 2)
Tobacco Use Disorder (Phase 2)
Tongue (Phase 4)
Vascular Stiffness (Phase 4)
Weight Loss (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue